Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
AF, SVT, and VT catheter ablation. Main billing specialties: cardiology and electrophysiology.
Medicare fee-for-service EP ablation cases in the 49 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 189 | 11,766+7.3%/yr | +7.3%/yr | 4.31.3× | 0% | 19,400 in 2030+8.6%/yr |
| California | 165 | 11,552+8.2%/yr | +8.2%/yr | 2.90.9× | 0% | 21,900 in 2030+11%/yr |
| Texas | 177 | 10,931+7.5%/yr | +7.5%/yr | 4.21.2× | 0% | 20,900 in 2030+11%/yr |
| New York | 138 | 7,854+9.3%/yr | +9.3%/yr | 3.61.1× | 0% | 15,300 in 2030+12%/yr |
| Pennsylvania | 131 | 5,803+11%/yr | +11%/yr | 3.51.1× | 0% | 11,400 in 2030+12%/yr |
| Illinois | 109 | 5,700+7.4%/yr | +7.4%/yr | 3.61.1× | 0% | 10,500 in 2030+11%/yr |
| Virginia | 75 | 5,013+9.4%/yr | +9.4%/yr | 4.21.2× | 0% | 9,220 in 2030+11%/yr |
| Ohio | 100 | 4,592+3.6%/yr | +3.6%/yr | 3.41.0× | 0% | 7,400 in 2030+8.3%/yr |
| Massachusetts | 73 | 4,222+12%/yr | +12%/yr | 4.01.2× | 0% | 9,560 in 2030+15%/yr |
| North Carolina | 76 | 3,911+8.1%/yr | +8.1%/yr | 3.31.0× | 0% | 6,900 in 2030+9.9%/yr |
| Arizona | 62 | 3,909+7.7%/yr | +7.7%/yr | 4.41.3× | 0% | 6,260 in 2030+8.2%/yr |
| Tennessee | 60 | 3,741+3.6%/yr | +3.6%/yr | 4.41.3× | 0% | 6,340 in 2030+9.2%/yr |
| Georgia | 65 | 3,401+5%/yr | +5%/yr | 3.31.0× | 0% | 7,490 in 2030+14%/yr |
| South Carolina | 41 | 3,270+9.7%/yr | +9.7%/yr | 4.11.2× | 0% | 6,810 in 2030+13%/yr |
| Indiana | 62 | 3,095+8.8%/yr | +8.8%/yr | 3.71.1× | 0% | 5,760 in 2030+11%/yr |
| New Jersey | 61 | 3,055+5.7%/yr | +5.7%/yr | 2.50.8× | 0% | 5,460 in 2030+10%/yr |
| Michigan | 66 | 2,682+0.7%/yr | +0.7%/yr | 2.60.8× | 0% | 4,190 in 2030+7.7%/yr |
| Washington | 49 | 2,678+2.4%/yr | +2.4%/yr | 2.90.9× | 0% | 4,000 in 2030+6.9%/yr |
| Colorado | 47 | 2,229+6.8%/yr | +6.8%/yr | 3.81.1× | 0% | 4,850 in 2030+14%/yr |
| Maryland | 43 | 2,173+8.6%/yr | +8.6%/yr | 2.30.7× | 0% | 3,610 in 2030+8.8%/yr |
| Alabama | 36 | 2,013+2.1%/yr | +2.1%/yr | 3.71.1× | 0% | 2,930 in 2030+6.5%/yr |
| Minnesota | 48 | 1,991+7%/yr | +7%/yr | 3.61.1× | 0% | 4,870 in 2030+16%/yr |
| Missouri | 37 | 1,982+3.6%/yr | +3.6%/yr | 2.70.8× | 0% | 3,810 in 2030+11%/yr |
| Wisconsin | 48 | 1,918+11%/yr | +11%/yr | 2.80.8× | 0% | 3,690 in 2030+12%/yr |
| Oklahoma | 23 | 1,684+4.1%/yr | +4.1%/yr | 3.00.9× | 0% | 2,960 in 2030+9.9%/yr |
| Kansas | 27 | 1,645+7.2%/yr | +7.2%/yr | 3.61.1× | 0% | 2,880 in 2030+9.8%/yr |
| Iowa | 27 | 1,505+14%/yr | +14%/yr | 3.00.9× | 0% | 2,760 in 2030+11%/yr |
| Arkansas | 15 | 1,494+3.9%/yr | +3.9%/yr | 3.41.0× | 0% | 2,460 in 2030+8.7%/yr |
| Kentucky | 30 | 1,317+6.3%/yr | +6.3%/yr | 2.40.7× | 0% | 2,610 in 2030+12%/yr |
| Louisiana | 27 | 1,317+5.2%/yr | +5.2%/yr | 2.70.8× | 0% | 2,790 in 2030+13%/yr |
| Utah | 20 | 1,253+6.8%/yr | +6.8%/yr | 4.81.4× | 0% | 2,180 in 2030+9.7%/yr |
| Oregon | 25 | 1,089+4.8%/yr | +4.8%/yr | 2.10.6× | 0% | 1,910 in 2030+9.9%/yr |
| Connecticut | 25 | 921+6%/yr | +6%/yr | 2.30.7× | 0% | 1,750 in 2030+11%/yr |
| Nebraska | 15 | 802+7.1%/yr | +7.1%/yr | 2.80.8× | 0% | 1,560 in 2030+12%/yr |
| Nevada | 16 | 764+6.9%/yr | +6.9%/yr | 2.20.7× | 0% | 1,620 in 2030+13%/yr |
| Montana | 10 | 763+16%/yr | +16%/yr | 3.61.1× | 0% | 1,730 in 2030+15%/yr |
| Mississippi | 10 | 693−0.9%/yr | −0.9%/yr | 1.60.5× | 0% | 1,160 in 2030+9%/yr |
| Idaho | 10 | 646+5.8%/yr | +5.8%/yr | 2.70.8× | 0% | 1,310 in 2030+12%/yr |
| West Virginia | 13 | 643+7.7%/yr | +7.7%/yr | 2.60.8× | 0% | 1,120 in 2030+9.8%/yr |
| New Hampshire | 11 | 595+16%/yr | +16%/yr | 2.30.7× | 0% | 1,590 in 2030+18%/yr |
| New Mexico | 8 | 559+9.8%/yr | +9.8%/yr | 2.00.6× | 0% | 1,040 in 2030+11%/yr |
| District of Columbia | 8 | 503+10%/yr | +10%/yr | 7.12.1× | 0% | 1,040 in 2030+13%/yr |
| Maine | 10 | 404+10%/yr | +10%/yr | 2.10.6× | 0% | 870 in 2030+14%/yr |
| Alaska | 4 | 397+5.8%/yr | +5.8%/yr | 3.31.0× | 0% | 740 in 2030+11%/yr |
| Rhode Island | 8 | 382+4.9%/yr | +4.9%/yr | 3.41.0× | 0% | 920 in 2030+16%/yr |
| South Dakota | 5 | 296+14%/yr | +14%/yr | 2.00.6× | 0% | 610 in 2030+13%/yr |
| Delaware | 7 | 268+0.4%/yr | +0.4%/yr | 1.40.4× | 0% | 330 in 2030+3.6%/yr |
| North Dakota | 5 | 223+7.5%/yr | +7.5%/yr | 2.00.6× | 0% | 500 in 2030+15%/yr |
| Vermont | 6 | 187+11%/yr | +11%/yr | 1.50.4× | 0% | 630 in 2030+22%/yr |
Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 972 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 8 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Abbott | 268 |
| Johnson & Johnson MedTech | 227 |
| Boston Scientific | 215 |
| Medtronic | 213 |
| Farapulse | 25 |
| Cardiofocus | 15 |
| Kardium | 7 |
| Stereotaxis | 2 |
Product codes: LPB (cardiac ablation percutaneous catheter), OAD (catheter, percutaneous, cardiac ablation, for treatment of atrial flutter), OAE (catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation), QZI (percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 20% of the cases CMS names in Florida; 100 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 3,039 | 159,222−3.4%/yr | −3.4%/yr | 164,900 in 2030+0.6%/yr |
| LAA occlusion & loop recorders | 2,939 | 120,836+10%/yr | +10%/yr | 217,900 in 2030+10%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 9 companies reported engagement with surgeons in the covered states worth $19M in consulting, speaking, meals and travel tied to these products, about $8,070 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.